MedImmune Deploys Targeted Antibodies In Battle Against Superbugs
Using the ICAAC annual meeting as a platform, MedImmune execs explain efforts to reinvigorate the company’s infectious disease pipeline. Early data suggest a possible supporting role for monoclonal antibody candidates in preventing and treating bacterial infections.
You may also be interested in...
The big pharma denies reports it is disbanding antibiotics research, but says it is continuing to explore partnering opportunities for its non-core portfolio, including infectious disease.
The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.
Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese
Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.